WntRx Pharmaceuticals develops non-toxic selective drugs for the treatment of patients with colorectal cancer and critical unmet medical needs. It specializes in the development of oncogenic-specific inhibitors of Wnt signaling, a pathway aberrantly activated in a multitude of cancers. The company was founded in 2013 and is headquartered inBoston, Massachusetts.

Biotechnology

Health Care

Pharmaceutical

WntRx Pharmaceuticals

WntRx Pharmaceuticals' headquarters in Boston, MA, United States

Jin Wang

Eric Cheng

Yanjun Ma

Yeung Heung Yeung

Andrew X. Zhu

Simon Fricker

Lixin Yang

Robert Perni

Paul D. Rennert

Description

People (1)

John Tagliamonte

Jobs